Insider Trading disclosures for CorMedix Inc

The latest disclosure was made by Steven W. Lefkowitz in CorMedix Inc where a trade of 20,000 Stock Option (Right to Buy Common Stock) done was reported to US exchanges on April 2, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Show

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Steven W. Lefkowitz	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	02 Apr 2025	20,000	0	-		-	Stock Option (Right to Buy Common Stock)
Steven W. Lefkowitz	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.03 per share.	02 Apr 2025	20,000	120,498 (0%)	0%	4.0	80,600	Common Stock
Joseph Todisco	Director, Chief Executive Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.38 per share.	01 Apr 2025	59,170	530,721 (2%)	0%	3.4	199,995	Common Stock
Joseph Todisco	Director, Chief Executive Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	01 Apr 2025	59,170	440,830	-		-	Stock Option (Right to Buy Common Stock)
Myron Kaplan	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Jan 2025	25,000	176,034 (0%)	0%		0	Common Stock
Alan W. Dunton	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Jan 2025	25,000	40,250 (0%)	0%		0	Common Stock
Steven W. Lefkowitz	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Jan 2025	25,000	100,498 (0%)	0%		0	Common Stock
Janet M. Dillione	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Jan 2025	25,000	78,473 (0%)	0%		0	Common Stock
Gregory Duncan	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Jan 2025	25,000	25,000 (0%)	0%		0	Common Stock
Joseph Todisco	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Jan 2025	187,500	495,528 (1%)	0%		0	Common Stock
Joseph Todisco	Director, Chief Executive Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.17 per share.	17 Jan 2025	23,977	471,551 (1%)	0%	12.2	291,800	Common Stock
Elizabeth Hurlburt	EVP	Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.19 per share.	10 Jan 2025	5,790	115,728 (0%)	0%	11.2	64,790	Common Stock
Joseph Todisco	Director, Chief Executive Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.19 per share.	10 Jan 2025	17,829	308,028 (1%)	0%	11.2	199,507	Common Stock
Matthew T. David	Chief Financial Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.19 per share.	10 Jan 2025	6,515	95,270 (0%)	0%	11.2	72,903	Common Stock
Erin Mistry	EVP, Chief Commercial Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.19 per share.	10 Jan 2025	5,689	100,992 (0%)	0%	11.2	63,660	Common Stock
Elizabeth Hurlburt	EVP	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	87,500	132,897 (0%)	0%		0	Common Stock
Elizabeth Hurlburt	EVP	Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.22 per share.	02 Jan 2025	11,378	121,519 (0%)	0%	8.2	93,527	Common Stock
Matthew T. David	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	62,500	110,434 (0%)	0%		0	Common Stock
Matthew T. David	Chief Financial Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.22 per share.	02 Jan 2025	8,648	101,786 (0%)	0%	8.2	71,087	Common Stock
Erin Mistry	EVP, Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	62,500	114,511 (0%)	0%		0	Common Stock
Erin Mistry	EVP, Chief Commercial Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.22 per share.	02 Jan 2025	7,830	106,681 (0%)	0%	8.2	64,363	Common Stock
Beth Zelnick Kaufman	Chief Legal Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	87,500	131,456 (0%)	0%		0	Common Stock
Beth Zelnick Kaufman	Chief Legal Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.22 per share.	02 Jan 2025	11,844	119,612 (0%)	0%	8.2	97,358	Common Stock
Beth Kaufman Zelnick	Chief Legal Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.77 per share.	16 Dec 2024	6,044	43,956 (0%)	0%	8.8	53,006	Common Stock
Beth Zelnick Kaufman	Chief Legal Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Dec 2024	12,500	62,500 (0%)	0%		-	Common Stock
Beth Zelnick Kaufman	Chief Legal Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	12 Dec 2024	12,500	37,500	-		-	Restricted Stock Units
Beth Zelnick Kaufman	Chief Legal Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.77 per share.	12 Dec 2024	6,044	56,456 (0%)	0%	8.8	53,006	Common Stock
Elizabeth Hurlburt	EVP	Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.33 per share.	14 Nov 2024	3	45,400 (0%)	0%	1.3	4	Common Stock
Elizabeth Hurlburt	EVP	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	14 Nov 2024	25,000	75,000	-		-	Stock Option (Right to Buy Common Stock)
Elizabeth Hurlburt	EVP	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	14 Nov 2024	62,500	62,500	-		-	Stock Option (Right to Buy Common Stock)
Elizabeth Hurlburt	EVP	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	14 Nov 2024	34,467	3,033	-		-	Stock Option (Right to Buy Common Stock)
Elizabeth Hurlburt	EVP	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	14 Nov 2024	9,888	27,612	-		-	Stock Option (Right to Buy Common Stock)
Elizabeth Hurlburt	EVP	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	14 Nov 2024	8,169	12,711	-		-	Stock Option (Right to Buy Common Stock)
Elizabeth Hurlburt	EVP	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	14 Nov 2024	3	53,997	-		-	Stock Option (Right to Buy Common Stock)
Elizabeth Hurlburt	EVP	Sale of securities on an exchange or to another person at price $ 11.18 per share.	14 Nov 2024	140,027	45,397 (0%)	0%	11.2	1,565,670	Common Stock
Elizabeth Hurlburt	EVP	Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.47 per share.	14 Nov 2024	25,000	185,424 (0%)	0%	3.5	86,750	Common Stock
Elizabeth Hurlburt	EVP	Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.43 per share.	14 Nov 2024	62,500	160,424 (0%)	0%	4.4	276,875	Common Stock
Elizabeth Hurlburt	EVP	Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.08 per share.	14 Nov 2024	34,467	97,924 (0%)	0%	4.1	140,625	Common Stock
Elizabeth Hurlburt	EVP	Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.63 per share.	14 Nov 2024	9,888	63,457 (0%)	0%	5.6	55,669	Common Stock
Elizabeth Hurlburt	EVP	Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.30 per share.	14 Nov 2024	8,169	53,569 (0%)	0%	8.3	67,803	Common Stock
Erin Mistry	EVP, Chief Commercial Officer	Purchase of securities on an exchange or from another person at price $ 9.99 per share.	31 Oct 2024	1,500	52,011 (0%)	0%	10.0	14,985	Common Stock
Joseph Todisco	Director, Chief Executive Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.17 per share.	10 May 2024	26,982	325,857 (1%)	0%	5.2	139,497	Common Stock
Joseph Todisco	Director, Chief Executive Officer	Purchase of securities on an exchange or from another person at price $ 3.74 per share.	13 Mar 2024	13,561	352,839 (1%)	0%	3.7	50,718	Common Stock
Myron Kaplan	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	05 Mar 2024	30,000	30,000	-		-	Stock Option (Right to Buy Common Stock)
Alan W. Dunton	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	05 Mar 2024	30,000	30,000	-		-	Stock Option (Right to Buy Common Stock)
Steven W. Lefkowitz	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	05 Mar 2024	30,000	30,000	-		-	Stock Option (Right to Buy Common Stock)
Janet M. Dillione	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	05 Mar 2024	30,000	30,000	-		-	Stock Option (Right to Buy Common Stock)
Gregory Duncan	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	05 Mar 2024	30,000	30,000	-		-	Stock Option (Right to Buy Common Stock)
Erin Mistry	Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Jan 2024	50,000	54,900 (0%)	0%		0	Common Stock
David Matthew T.	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Jan 2024	100,000	100,000	-		-	Stock Option (Right to Buy Common Stock)

Showing 1 to 50 of 500 entries

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

34.30% Fall from 52W High

Insider Trading disclosures for CorMedix Inc

The latest disclosure was made by Steven W. Lefkowitz in CorMedix Inc where a trade of 20,000 Stock Option (Right to Buy Common Stock) done was reported to US exchanges on April 2, 2025.

Screeners based on Insider Trading and SAST parameters